AGN argenica therapeutics limited

AGN Media thread, page-98

  1. 1,367 Posts.
    lightbulb Created with Sketch. 178
    NYR reduces secondary brain injury via the reduction of calcium influx in the brain cell

    AGN reduces secondary and brain injury via the reduction of calcium influx in the brain cell

    You are not the only drug that does what it does. NYR is a drug molecule, AGN is a peptide. NYR is more readily available as a molecule and worth significantly less to produce and the formulations it can come in are significantly greater

    Both will revolutionise the secondary brain injury space but don’t think your alone. However to compare market caps of 6 million for NYR and 100 million for AGN when both work the same to reduce secondary brain injury by reducing calcium influx by inhibiting the receptors on the brain cell in charge of allowing calcium in. The bigger return of investment right now is the other
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
65.5¢
Change
-0.025(3.68%)
Mkt cap ! $84.13M
Open High Low Value Volume
68.0¢ 68.0¢ 65.5¢ $61.17K 91.97K

Buyers (Bids)

No. Vol. Price($)
2 10877 65.5¢
 

Sellers (Offers)

Price($) Vol. No.
67.0¢ 42597 1
View Market Depth
Last trade - 16.10pm 21/07/2025 (20 minute delay) ?
AGN (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.